American Association for Cancer Research

Skip to Main Content

Table 3

ORs^a for prostate cancer in relation to AIB/SRC-3 CAG/CAA and AR CAG or GGN repeat lengths in Chinese men

AR polymorphisms	CAG/CAA repeat length genotypes of the AIB1/SRC-3 gene
		29/29					<29/29					<29/<29					>29/29					>29/<29
		n₁/n₂^b	OR	95% CI	n₁/n₂	OR	95% CI	n₁/n₂	OR	95% CI	n₁/n₂	OR	95% CI	n₁/n₂	OR	95% CI
CAG repeat length^c
≥23	29/64	1.00		31/65	1.05	0.57–1.94	9/14	1.42	0.55–3.66	1/4	0.55	0.06–5.20	4/4	2.21	0.51–9.48
<23	37/64	1.27	0.70–2.32	50/55	2.00	1.12–3.59	19/15	2.78	1.24–6.26	8/7	2.50	0.83–7.60	1/3	0.72	0.07–7.34
GGN repeat length^c
≥23	49/104	1.00		69/93	1.57	0.99–2.49	19/23	1.75	0.87–3.51	8/8	2.12	0.75–5.99	3/6	1.06	0.25–4.42
<23	16/23	1.47	0.71–3.04	12/24	1.07	0.49–2.31	7/6	2.47	0.79–7.77	1/3	0.70	0.07–6.94	2/0

AR polymorphisms	CAG/CAA repeat length genotypes of the AIB1/SRC-3 gene
		29/29					<29/29					<29/<29					>29/29					>29/<29
		n₁/n₂^b	OR	95% CI	n₁/n₂	OR	95% CI	n₁/n₂	OR	95% CI	n₁/n₂	OR	95% CI	n₁/n₂	OR	95% CI
CAG repeat length^c
≥23	29/64	1.00		31/65	1.05	0.57–1.94	9/14	1.42	0.55–3.66	1/4	0.55	0.06–5.20	4/4	2.21	0.51–9.48
<23	37/64	1.27	0.70–2.32	50/55	2.00	1.12–3.59	19/15	2.78	1.24–6.26	8/7	2.50	0.83–7.60	1/3	0.72	0.07–7.34
GGN repeat length^c
≥23	49/104	1.00		69/93	1.57	0.99–2.49	19/23	1.75	0.87–3.51	8/8	2.12	0.75–5.99	3/6	1.06	0.25–4.42
<23	16/23	1.47	0.71–3.04	12/24	1.07	0.49–2.31	7/6	2.47	0.79–7.77	1/3	0.70	0.07–6.94	2/0

^a

Adjusted for age.

^b

n₁ number of cases; n₂, number of controls.

^c

Median number of repeats among controls was used for the cutoff.